These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27332629)

  • 1. Improvement in Symptoms of Autism Spectrum Disorder in Children With the Use of Gastrin-Releasing Peptide: An Open Trial.
    Becker MM; Riesgo RS; Roesler R; Bosa C; Ohlweiler L; Backes B; Endres RG; Zanon RB; Marchezan J; Schwartsmann G
    Clin Neuropharmacol; 2016; 39(5):215-9. PubMed ID: 27332629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism.
    Marchezan J; Becker M; Schwartsmann G; Ohlweiler L; Roesler R; Renck LB; Gonçalves MMM; Ranzan J; Riesgo RDS
    Clin Neuropharmacol; 2017; 40(3):108-112. PubMed ID: 28452904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of autism spectrum disorder symptoms in three children by using gastrin-releasing peptide.
    Becker MM; Bosa C; Oliveira-Freitas VL; Goldim JR; Ohlweiler L; Roesler R; Schwartsmann G; Riesgo Rdos S
    J Pediatr (Rio J); 2016; 92(3):302-6. PubMed ID: 26893210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, open-label trial of galantamine in autistic disorder.
    Nicolson R; Craven-Thuss B; Smith J
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):621-9. PubMed ID: 17069550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder.
    Zimmerman AW; Singh K; Connors SL; Liu H; Panjwani AA; Lee LC; Diggins E; Foley A; Melnyk S; Singh IN; James SJ; Frye RE; Fahey JW
    Mol Autism; 2021 May; 12(1):38. PubMed ID: 34034808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.
    Hellings JA; Reed G; Cain SE; Zhou X; Barth FX; Aman MG; Palaguachi GI; Mikhnev D; Teng R; Andridge R; Logan M; Butler MG; Han JC
    J Child Adolesc Psychopharmacol; 2015 Mar; 25(2):150-9. PubMed ID: 25782098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism.
    Hendren RL; James SJ; Widjaja F; Lawton B; Rosenblatt A; Bent S
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):774-783. PubMed ID: 26889605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series.
    Rothman J; Bartky EJ; Halas FP
    Clin Ther; 2019 Oct; 41(10):1972-1981. PubMed ID: 31492568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Low-Level Laser Therapy in Autism Spectrum Disorder.
    Leisman G; Machado C; Machado Y; Chinchilla-Acosta M
    Adv Exp Med Biol; 2018; 1116():111-130. PubMed ID: 29956199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
    Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ;
    Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.
    Wink LK; Pedapati EV; Horn PS; McDougle CJ; Erickson CA
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):91-94. PubMed ID: 26465194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial.
    Malek M; Ashraf-Ganjouei A; Moradi K; Bagheri S; Mohammadi MR; Akhondzadeh S
    Clin Neuropharmacol; 2020; 43(2):39-45. PubMed ID: 32168067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.
    King BH; Wright DM; Handen BL; Sikich L; Zimmerman AW; McMahon W; Cantwell E; Davanzo PA; Dourish CT; Dykens EM; Hooper SR; Jaselskis CA; Leventhal BL; Levitt J; Lord C; Lubetsky MJ; Myers SM; Ozonoff S; Shah BG; Snape M; Shernoff EW; Williamson K; Cook EH
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):658-65. PubMed ID: 11392343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder.
    Joshi G; Wozniak J; Faraone SV; Fried R; Chan J; Furtak S; Grimsley E; Conroy K; Kilcullen JR; Woodworth KY; Biederman J
    J Clin Psychopharmacol; 2016 Jun; 36(3):262-71. PubMed ID: 27043118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bumetanide for Autism Spectrum Disorder in Children: A Review of Randomized Controlled Trials.
    James BJ; Gales MA; Gales BJ
    Ann Pharmacother; 2019 May; 53(5):537-544. PubMed ID: 30501497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.
    Lemonnier E; Villeneuve N; Sonie S; Serret S; Rosier A; Roue M; Brosset P; Viellard M; Bernoux D; Rondeau S; Thummler S; Ravel D; Ben-Ari Y
    Transl Psychiatry; 2017 Mar; 7(3):e1056. PubMed ID: 28291262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders.
    Taliou A; Zintzaras E; Lykouras L; Francis K
    Clin Ther; 2013 May; 35(5):592-602. PubMed ID: 23688534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
    Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.